Replies to post #35021 on Relief Therapeutics Holding AG (RLFTF)

[Toohie]

Well the inhaled Aviptadil could get EUA in the summer, plus it shows that there is a very strong possibility that the critical trial is a success

[4running]

Because as a small biotech with the need to spend responsibly; doesn't just off the cuff have millions in expenditures to start new trials.

You don't just have strategic teams behind navigating FDA and statistical output on a whim IMO

Thats why RLFTF makes me exited, I think those behind this crusade are bulls with horns sharpened ; they see red tape, and are preparing to tear right through it imo.

[soliloquy]

I’ve been here since the 1st week of August so according to you from then till now is forever. I see a big payday any day now. Which hopefully will be one of several nice pops as things progress!! Good things come to those who wait. GLTY!

[Tiger Money]

BECAUSE they wouldn't move forward with that study if intravenous VIP (RLF-100) wasn't a slam dunk. It is like icing on the cake or more revenue and I mean in an efficient manner. In two months, you can simply go to wallgreens or CVS and pick up your little puffer full of VIP if you feel like you are coming down with something called COVID-19. connect the dots. all that study does is make RLF-100 AVAILABLE EVERYWHERE instead of a pain in the ass intravenous method....it is about ease and ease is about a shit ton more revenue.... that is why peps are jacked!

[TurdBlossom]

The Aviptadil inhalation trial is huge news especially since the age group to be studied is 12-85 yrs old. Currently those under the age of 21 are not a priority for vaccination because they account for 0.08% of Covid19 related deaths in the US, yet those under 21 account for about 26% of the US population.
Children can get sick from the Covid19 virus and children can suffer longer term effects, like multi system inflammatory disease of children (MISC). Should additional studies demonstrate that a VIP inhaler administered at home is safe and effective for the pediatric population, we are looking at the key to returning to a normal life at the very least and very possibly a novel SOC for how viral respiratory infections are treated. Exciting times! IMO